« Return to News | R&D Trends | CROs/Service Providers

New CenterWatch Report Examines Japan’s Surging Clinical Trials Market

Wednesday, April 1, 2009 03:00 PM

In 2007, drug development in Japan, the world’s second largest pharmaceutical market, exploded six-fold over 2006 and should continue to grow, according to a new CenterWatch report released today.

Japan: Opening the Door to Global Clinical Trials, the fourth in a series of CenterWatch reports on global clinical research markets, takes a look at the reasons for Japan’s dramatic growth, the differences in the country’s approach to clinical research, and government initiatives to attract Big Pharma to conduct simultaneous global clinical trials in Japan.

“New government initiatives have helped to streamline drug review and approval processes, and sponsor companies have responded by including Japan in their global drug development programs more,” said Sara Gambrill, senior editor at CenterWatch and author of the report. “Japan is participating in global drug development at historic levels; however, there is still work to be done there to sustain that growth.”

This is an essential resource for any business seeking to better understand Japan’s clinical trials landscape and what to expect when conducting clinical research there.
 
To purchase Japan: Opening the Door to Global Clinical Trials, visit the CenterWatch bookstore.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.